Overview

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide scientific basis for the formulation of the best comprehensive treatment plan in the future.

Phase:

Phase 2

Details

Lead Sponsor:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Treatments:

Antibodies, Monoclonal
Carboplatin
Cisplatin
Durvalumab
Etoposide